HONG KONG – GNT Pharma Co. Ltd., of Yongin City, South Korea, has finished the patient enrollment for a phase II trial of its multitarget neuroprotection candidate, Neu-2000, in China, with top-line results from the trial, known as ENIS, expected in the first half of this year.